Pharmacogenetics of tomorrow: The 1 + 1 = 3 principle

Pharmacogenomics

Volumn 11, Issue 7, 2010, Pages 1011-1017

  Pander, Jan ^a   Wessels, Judith Am ^a   Mathijssen, Ron Hj ^b   Gelderblom, Hans ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

classification and regression tree; multifactor dimensionality reduction; pharmacogenetics; sunitinib; toxicity

Indexed keywords

SUNITINIB;

ABCB1 GENE; CLASSIFICATION AND REGRESSION TREE ANALYSIS; CLASSIFIER; CYP1A2 GENE; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; MULTIFACTOR DIMENSIONALITY REDUCTION; NR1I3 GENE; PHARMACOGENETICS; PREDICTION; REVIEW; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; FORECASTING; HUMANS; MULTIFACTOR DIMENSIONALITY REDUCTION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RESEARCH DESIGN;

EID: 77954366144     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.87     Document Type: Review

References (25)

1. Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet 361(9360), 865-872 (2003).
2. Braun MS, Richman SD, Thompson L et al.: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J. Clin. Oncol. 27(33), 5519-5528 (2009).
3. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 25(29), 4528-4535 (2007).
4. Grossman I, Sullivan PF, Walley N et al.: Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet. Med. 10(10), 720-729 (2008).
5. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat. Genet. 29(3), 306-309 (2001).
6. Ikediobi ON, Shin J, Nussbaum RL et al.: Addressing the challenges of the clinical application of pharmacogenetic testing. Clin. Pharmacol. Ther. 86(1), 28-31 (2009).
7. Kooloos WM, Wessels JA, van der Straaten T, Huizinga TW, Guchelaar HJ: Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. Drug Discov. Today 14(17-18), 837-844 (2009).
8. Wilke RA, Reif DM, Moore JH: Combinatorial pharmacogenetics. Nat. Rev. Drug Discov. 4(11), 911-918 (2005).
9. Baker SD, Verweij J, Cusatis GA et al.: Pharmacogenetic pathway ana lysis of docetaxel elimination. Clin. Pharmacol. Ther. 85(2), 155-163 (2009).
10. Beretta L, Cappiello F, Moore JH, Barili M, Greene CS, Scorza R: Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis Rheum. 59(7), 974-983 (2008).
11. Menon R, Velez DR, Simhan H et al.: Multilocus interactions at maternal tumor necrosis factor-a, tumor necrosis factor receptors, interleukin-6 and interleukin-6 receptor genes predict spontaneous preterm labor in European-American women. Am. J. Obstet. Gynecol. 194(6), 1616-1624 (2006).
12. Tsai CT, Lai LP, Lin JL et al.: Renin-angiotensin system gene polymorphisms and atrial fbrillation. Circulation 109(13), 1640-1646 (2004).
13. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J: Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 112(11), 2467-2474 (2008).
14. Ye Y, Lippman SM, Lee JJ et al.: Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer 113(9), 2488-2495 (2008).
15. Gupta M, Chauhan C, Bhatnagar P et al.: Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms. Pharmacogenomics 10(2), 277-291 (2009).
16. Gordon MA, Gil J, Lu B et al.: Genomic profling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 7(1), 67-88 (2006).
17. Wilke RA, Moore JH, Burmester JK: Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet. Genomics 15(6), 415-421 (2005).
18. Dervieux T, Wessels JA, van der Straaten T et al.: Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet. Genomics 19(12), 935-944 (2009).
19. Pérez-Pérez JM, Candela H, Micol JL: Understanding synergy in genetic interaction. Trends Genet. 25(8), 368-376 (2009).
20. Moore JH, Gilbert JC, Tsai CT et al.: A fexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J. Theor. Biol. 241(2), 252-261 (2006).
21. van Erp NP, Eechoute K, van der Veldt AA et al.: Pharmacogenetic pathway ana lysis for determination of sunitinib-induced toxicity. J. Clin. Oncol. 27(26), 4406-4412 (2009).
22. Ritchie MD, Motsinger AA: Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies. Pharmacogenomics 6(8), 823-834 (2005).
23. Pattin KA, White BC, Barney N et al.: A computationally effcient hypothesis testing method for epistasis ana lysis using multifactor dimensionality reduction. Genet. Epidemiol. 33(1), 87-94 (2009).
24. Moore JH, Ritchie MD: The challenges of whole-genome approaches to common diseases. JAMA 291(13), 1642-1643 (2004).
25. Altman DG, Vergouwe Y, Royston P, Moons KG: Prognosis and prognostic research: validating a prognostic model. BMJ 338, B605 (2009).